Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 First-in-human Study of U3-1402 (HER3-DXd) in HER3-positive Metastatic Breast Cancer
jRCT2080223346Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of U3-1402 (HER3-DXd) and Determination of recommended dose for expansion. Started Oct 2016; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223346.